Mindfulness Program for Blood Sugar Control, Heart Rate Variability, Anxiety, and Depression in Type 2 Diabetes
Effect of a Six-Week Mindfulness-Based Intervention on Glycemic Control, Cardiovascular Autonomic Function, Anxiety, and Depression in Adults With Type 2 Diabetes: A Randomized Controlled Trial
The goal of this clinical trial was to learn whether a six-week mindfulness program, added to standard diabetes treatment, improves blood sugar control, heart rate variability (a measure of how the nervous system regulates the heart), anxiety, and depression in adults aged 18 to 60 years with type 2 diabetes. The main questions it aimed to answer were:
- Does the mindfulness program lower glycated hemoglobin (HbA1c), fasting blood glucose, and 2-hour postprandial blood glucose?
- Does it improve heart rate variability, cardiovascular autonomic dysfunction status, and anxiety and depression scores?
Researchers compared participants who received standard therapy plus the mindfulness program with participants who received standard therapy alone.
Participants in the mindfulness group listened to weekly audio-guided practices sent through WhatsApp (mindful eating, breathing exercise, body scan, mindful walking, dealing with unpleasant experiences, and loving-kindness meditation) and were asked to practice daily for six weeks. All participants had blood tests, a 3-minute heart rate variability recording, and the Hospital Anxiety and Depression Scale questionnaire at the start of the study and after six weeks.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This single-center, parallel-group randomized controlled trial with a pretest-posttest design was conducted at the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, Indonesia, from March to June 2025. Adults with type 2 diabetes receiving antidiabetic treatment were randomly allocated in a 1:1 ratio to standard therapy plus a six-week mindfulness program (intervention) or standard therapy alone (control).
The mindfulness program was adapted from a mindfulness-based stress reduction (MBSR) handbook and consisted of one theme per week: mindful eating, breathing exercise, body scan, staying present (mindful walking), dealing with unpleasant experiences, and loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants were asked to practice daily (approximately 20 minutes per day) and received regular reminders.
Outcomes were assessed at baseline and after six weeks. HbA1c was measured with a point-of-care analyzer (Afinion HbA1c, Abbott); fasting and 2-hour postprandial venous blood glucose were measured with an enzymatic photometric method in the hospital laboratory. Short-term heart rate variability was recorded for 3 minutes with a fingertip photoplethysmographic sensor (SA-3000P, Medicore), and cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. Anxiety and depression were assessed with the Indonesian version of the Hospital Anxiety and Depression Scale.
The sample size (13 per group, increased to 14 per group to allow for 10% attrition; 28 in total) was calculated with OpenEpi (two-sided alpha 0.05, power 80%). Between-group comparisons used the independent t-test or Mann-Whitney U test, within-group comparisons used the paired t-test or Wilcoxon signed-rank test, and changes in autonomic dysfunction status were analyzed with the McNemar test.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Central Java
-
Surakarta, Central Java, Indonesia, 57126
- Dr. Moewardi General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18-60 years with type 2 diabetes mellitus
- Receiving antidiabetic treatment
- Attending the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital
- Willing to participate and provided written informed consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Thyroid disorders
- Cardiac arrhythmia
- Use of drugs that may affect heart rate variability (e.g., beta-blockers, antidepressants, antipsychotics, or anxiolytics)
- Coffee consumption within 1 week before the start of the study
- Anemia (hemoglobin <13 g/dL in men or <12 g/dL in women)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Mindfulness plus standard therapy
Participants continued their standard antidiabetic therapy and completed a six-week audio-guided mindfulness program delivered through WhatsApp. |
A six-week mindfulness program adapted from a mindfulness-based stress reduction (MBSR) handbook, with one theme per week: (1) mindful eating, (2) breathing exercise, (3) body scan, (4) staying present - mindful walking, (5) dealing with unpleasant experiences, and (6) loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants practiced daily (approximately 20 minutes per day) and received regular reminders, in addition to standard antidiabetic therapy.
Altri nomi:
|
|
Nessun intervento: Standard therapy
Participants continued their standard antidiabetic therapy without the mindfulness program. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in glycated hemoglobin (HbA1c)
Lasso di tempo: Baseline and 6 weeks
|
HbA1c (%) measured with a point-of-care analyzer (Afinion HbA1c, Abbott). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in fasting blood glucose
Lasso di tempo: Baseline and 6 weeks
|
Venous blood glucose after an 8-10-hour fast, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in 2-hour postprandial blood glucose
Lasso di tempo: Baseline and 6 weeks
|
Venous blood glucose 2 hours after a meal, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in standard deviation of normal-to-normal intervals (SDNN)
Lasso di tempo: Baseline and 6 weeks
|
Short-term heart rate variability (ms) from a 3-minute recording with a fingertip photoplethysmographic sensor (SA-3000P, Medicore). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Number of participants with cardiovascular autonomic dysfunction
Lasso di tempo: Baseline and 6 weeks
|
Cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) score
Lasso di tempo: Baseline and 6 weeks
|
HADS anxiety subscale, range 0-21; higher scores indicate more severe anxiety symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) score
Lasso di tempo: Baseline and 6 weeks
|
HADS depression subscale, range 0-21; higher scores indicate more severe depressive symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Farha Naily Fawzia, MD, Universitas Sebelas Maret
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie del sistema nervoso
- Disordini mentali
- Malattie neuromuscolari
- Malattie metaboliche
- Sintomi comportamentali
- Malattie del sistema nervoso periferico
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Complicanze del diabete
- Comportamento
- Malattie nutrizionali e metaboliche
- Disturbi d'ansia
- Diabete mellito, tipo 2
- Depressione
- Neuropatie diabetiche
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2.765/XII/HREC/2024
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data will not be made publicly available to protect participant privacy; de-identified data may be obtained from the principal investigator upon reasonable request.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .